Table 4 Independent predictors of adverse cardiovascular events during follow-up, Cox regression analysis

Age years

1.02 (0.99–1.04)

1.02 (0.99–1.02)

0.230

Female sex

0.54 (2.27–1.08)

0.52 (0.24–1.14)

0.104

Clinical presentation^a

 DCM and/or heart failure

1.25 (0.65–2.43)

 Ventricular arrhythmias

0.93 (0.32–2.70)

 Renal insufficiency

2.23 (1.16–4.31)

2.19 (1.05–4.55)

0.036

 LVEF

0.98 (0.96–0.99)

1.00 (0.97–1.03)

0.781

 LVEDVI

1.01 (1.00–1.02)

1.00 (0.99–1.01)

1.180

Myocardial segments with enhancement^b

 2 segments

2.26 (0.98–5.19)

2.32 (0.97–5.83)

0,058

 ≥ 3 segments

2.97 (1.26–6.95)

2,71 (1.04–7.04)

0,040

 Aspirin

1.32 (0.72–2.44)

 Dual antiplatelet therapy

0.77 (0.42–1.43)

 Oral anticoagulants

1.43 (0.77–2.65)

 Beta-blockers

0.15 (0.62–2.14)

 ACEI/ARB

1.12 (0.58–2.16)

 Statins

0.78 (0.42–1.45)